X4 Pharmaceuticals Inc (NAS:XFOR)

$ 0.97355 0.07045 (7.8%) Market Cap: 163.49 Mil Enterprise Value: 131.19 Mil PE Ratio: 0 PB Ratio: 97.36 GF Score: 37/100

Q1 2024 X4 Pharmaceuticals Inc Earnings Call Transcript
May 07, 2024

$1.09 (-9.17%)

Earnings
Q4 2023 X4 Pharmaceuticals Inc Earnings Call Transcript
Mar 21, 2024

$1.31 (+28.43%)

Earnings
Q3 2023 X4 Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2023

$0.79 (+6.68%)

Earnings
X4 Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
X4 Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Q2 2023 X4 Pharmaceuticals Inc Earnings Call Transcript
Aug 10, 2023

$1.05 (-35.98%)

Earnings
X4 Pharmaceuticals Inc 4WHIM Phase 3 Clinical Trial Update Call Transcript
May 16, 2023
Q1 2023 X4 Pharmaceuticals Inc Earnings Call Transcript
May 04, 2023

$1.54 (+4.05%)

Earnings
Q4 2022 X4 Pharmaceuticals Inc Earnings Call Transcript
Mar 21, 2023

$0.8954 (+0.97%)

Earnings
X4 Pharmaceuticals Inc To Discuss Key Top-Line 4WHIM Trial Results Transcript
Nov 29, 2022
X4 Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
Nov 15, 2022
Q3 2022 X4 Pharmaceuticals Inc Earnings Call Transcript
Nov 03, 2022

$1.89 (-3.57%)

Earnings
X4 Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript
Aug 11, 2022
Q2 2022 X4 Pharmaceuticals Inc Earnings Call Transcript
Aug 04, 2022

$1.27 (-1.55%)

Earnings
Q1 2022 X4 Pharmaceuticals Inc Earnings Call Transcript
May 12, 2022

$1.04 (-0.95%)

Earnings
X4 Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Apr 14, 2022
X4 Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Q4 2021 X4 Pharmaceuticals Inc Earnings Call Transcript
Mar 17, 2022

$1.77 (-10.61%)

Earnings
X4 Pharmaceuticals Inc at B Riley Oncology Conference (Virtual) Transcript
Jan 28, 2022
Q3 2021 X4 Pharmaceuticals Inc Earnings Call Transcript
Nov 04, 2021

$5.15 (-8.04%)

Earnings
X4 Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Q2 2021 X4 Pharmaceuticals Inc Earnings Call Transcript
Aug 03, 2021

$5.66 (-4.55%)

Earnings
Q1 2021 X4 Pharmaceuticals Inc Earnings Call Transcript
May 06, 2021

$8.12 (+1.50%)

Earnings
Q4 2020 X4 Pharmaceuticals Inc Earnings Call Transcript
Mar 04, 2021

$9.18 (-5.75%)

Earnings
X4 Pharmaceuticals Inc Dr. Ragan Discusses X4's Work To Advance Disease-Modifying Therapies For Rare Genetic Diseases Transcript
Dec 23, 2020
Q3 2020 X4 Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2020

$6.01 (-6.68%)

Earnings
Q2 2020 X4 Pharmaceuticals Inc Earnings Call Transcript
Jul 30, 2020

$7.73 (-3.50%)

Earnings
X4 Pharmaceuticals Inc Post-EHA Corporate Update Transcript
Jun 12, 2020
Q1 2020 X4 Pharmaceuticals Inc Earnings Call Transcript
May 07, 2020

$8.56 (-4.89%)

Earnings
X4 Pharmaceuticals Inc Virtual Analyst Day - A Deep Dive into WHIM Syndrome Transcript
Apr 07, 2020
Q4 2019 X4 Pharmaceuticals Inc Earnings Call Transcript
Mar 12, 2020

$8.13 (-5.24%)

Earnings
Q3 2019 X4 Pharmaceuticals Inc Earnings Call Transcript
Nov 07, 2019

$13.41 (+3.79%)

Earnings

X4 Pharmaceuticals Inc 4WHIM Phase 3 Clinical Trial Update Call Transcript

May 16, 2023 / 08:00PM GMT

Release Date Price: $1.76 (+15.79%)

Transcript

Operator

Good afternoon and welcome to the X4 Pharmaceuticals webinar. (Operator Instructions)

It is now my pleasure to introduce our host for the event, Dr. Paula Ragan, Founder, President, and Chief Executive Officer of X4 Pharmaceuticals.

Paula Ragan

X4 Pharmaceuticals, Inc. - CEO & President

Thank you, and thanks to all of you for joining us today to review and discuss the exciting data from our Phase 3 trial of mavorixafor in WHIM syndrome.

Before we begin, I'd like to remind everyone that on today's call, we will be making forward-looking statements regarding our regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent forms 10-K and 10-Q, both on file with the SEC.

We will begin today's program with a brief overview of our lead investigational candidate, mavorixafor, and its potential to address the many unmet needs of individuals with WHIM syndrome and our

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.